Investigating how proteins that manage mitochondria affect brain cell function in Alzheimer's disease
Dynamin-related protein 1 and mitochondrial fission adapters regulate presynaptic function
['FUNDING_R01'] · UNIVERSITY OF NEVADA RENO · NIH-10930865
This study is looking at how a protein called DRP1 affects brain health in people with Alzheimer's disease, focusing on how it helps keep brain cells working well, with the hope of finding new ways to support brain function and slow down the disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF NEVADA RENO (nih funded) |
| Locations | 1 site (RENO, UNITED STATES) |
| Trial ID | NIH-10930865 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of dynamin-related protein 1 (DRP1) and its interaction with mitochondrial fission adapters in the brain, particularly in the context of Alzheimer's disease. The researchers aim to explore how these proteins influence the health and function of presynaptic terminals, which are crucial for neurotransmission. By examining the effects of mitochondrial dysfunction on synaptic transmission, the study seeks to identify potential therapeutic targets that could improve brain health and slow disease progression. The approach includes manipulating specific proteins and observing their impact on mitochondrial function and neuronal health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those experiencing early symptoms of cognitive decline.
Not a fit: Patients with non-neurological conditions or those without any cognitive impairment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve brain function and quality of life for patients with Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in targeting mitochondrial dysfunction as a therapeutic strategy in neurodegenerative diseases, suggesting that this approach may be effective.
Where this research is happening
RENO, UNITED STATES
- UNIVERSITY OF NEVADA RENO — RENO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RENDEN, ROBERT B — UNIVERSITY OF NEVADA RENO
- Study coordinator: RENDEN, ROBERT B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome